Emcure Pharmaceuticals has patented a ready-to-use carmustine solution for parenteral administration. The method involves adding the solution directly to saline or dextrose solutions without prior dilution. The stable liquid composition eliminates the need for reconstitution, providing convenience and efficiency in patient care. GlobalData’s report on Emcure Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Emcure Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Emcure Pharmaceuticals's grant share as of January 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11865206B2) outlines a method for administering carmustine to patients. The method involves providing a carmustine solution with a concentration ranging from 100 mg/mL to 500 mg/mL, along with a super refined polysorbate with specific peroxide values, in a sealed container free of certain materials. This solution is then directly added to a sodium chloride or dextrose injection solution without prior dilution, and subsequently administered to the patient parenterally. The method aims to streamline the administration process and ensure the stability and efficacy of the carmustine solution.
Furthermore, the patent specifies the use of specific polysorbates, particularly super refined polysorbate 80, and outlines storage conditions for the carmustine solution to maintain its integrity over time. The method emphasizes the importance of maintaining a specific oxygen level within the container and highlights the expected retention of carmustine concentration and absence of visible particles after storage at controlled temperatures. This innovative approach to carmustine administration could potentially improve patient outcomes and simplify the process for healthcare providers, offering a promising development in the field of pharmaceutical administration.
To know more about GlobalData’s detailed insights on Emcure Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
